562 related articles for article (PubMed ID: 36768610)
1. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
[TBL] [Abstract][Full Text] [Related]
2. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
3. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
Shorning BY; Dass MS; Smalley MJ; Pearson HB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
[TBL] [Abstract][Full Text] [Related]
4. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
5. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract][Full Text] [Related]
7. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
Tortorella E; Giantulli S; Sciarra A; Silvestri I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
9. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
Edlind MP; Hsieh AC
Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
11. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
Kim SM; Park JH; Kim KD; Nam D; Shim BS; Kim SH; Ahn KS; Choi SH; Ahn KS
Phytother Res; 2014 Mar; 28(3):423-31. PubMed ID: 23686889
[TBL] [Abstract][Full Text] [Related]
12. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
14. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
Choudhury AD
Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
[TBL] [Abstract][Full Text] [Related]
15. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
16. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
[TBL] [Abstract][Full Text] [Related]
17. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Gravina GL; Mancini A; Scarsella L; Colapietro A; Jitariuc A; Vitale F; Marampon F; Ricevuto E; Festuccia C
Tumour Biol; 2016 Jan; 37(1):341-51. PubMed ID: 26219891
[TBL] [Abstract][Full Text] [Related]
18. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
[TBL] [Abstract][Full Text] [Related]
19. A selective androgen receptor modulator, S4, displays robust anti-cancer activity on hepatocellular cancer cells by negatively regulating PI3K/AKT/mTOR signalling pathway.
Yavuz M; Takanlou LS; Avcı ÇB; Demircan T
Gene; 2023 Jun; 869():147390. PubMed ID: 36990257
[TBL] [Abstract][Full Text] [Related]
20. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
Cai F; Zhang Y; Li J; Huang S; Gao R
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
